| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:DW10075
CAS:1804982-31-7
Package:50mg/RMB 13800;25mg/RMB 10600;100mg/RMB 17500
|
1-Naphthalenecarboxamide, 6-[[2-[[3-(acetylamino)phenyl]amino]-4-pyrimidinyl]oxy]-N-phenyl- manufacturers
- DW10075
-
- $1980.00 / 50mg
-
2026-03-13
- CAS:1804982-31-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 1-Naphthalenecarboxamide, 6-[[2-[[3-(acetylamino)phenyl]amino]-4-pyrimidinyl]oxy]-N-phenyl- Basic information |
| | 1-Naphthalenecarboxamide, 6-[[2-[[3-(acetylamino)phenyl]amino]-4-pyrimidinyl]oxy]-N-phenyl- Chemical Properties |
| density | 1.365±0.06 g/cm3(Predicted) | | pka | 13.19±0.70(Predicted) |
| | 1-Naphthalenecarboxamide, 6-[[2-[[3-(acetylamino)phenyl]amino]-4-pyrimidinyl]oxy]-N-phenyl- Usage And Synthesis |
| Description | DW10075 is a novel potent and highly selective inhibitor of VEGFR, exhibiting antitumor activities both in vitro and in vivo. | | Uses | DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues. | | References | [1] DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo |
| | 1-Naphthalenecarboxamide, 6-[[2-[[3-(acetylamino)phenyl]amino]-4-pyrimidinyl]oxy]-N-phenyl- Preparation Products And Raw materials |
|